Drug development for metastatic castration-resistant prostate cancer: Current status and future perspectives - Abstract

Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA.


Prostate cancer represents a third of all newly diagnosed cancers in men in the USA with an estimated incidence of 192,280 cases and 27,360 deaths in 2009. It continues to be a major cause of cancer-related morbidity and mortality, and there is an urgent need for new treatments. Historically, systemic therapy options were limited after progression on docetaxel-based chemotherapy. This article reviews current data on the novel therapeutics demonstrating activity in metastatic castration-resistant prostate cancer and their future role in the treatment of this disease with a poor prognosis.

Written by:
Lassi K, Dawson NA.   Are you the author?

Reference: Future Oncol. 2011 Apr;7(4):551-8.
doi: 10.2217/fon.11.14

PubMed Abstract
PMID: 21463143

UroToday.com Prostate Cancer Section